Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure.
Mazouni C, Baggerly K, Hawke D, Tsavachidis S, André F, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of Changes in Plasma Protein Profiles during Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Using MALDI-TOF/MS Procedure. Cancer Research 2009, 69: 2037-2037. DOI: 10.1158/0008-5472.sabcs-09-2037.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyHER2-positive breast cancerResponse groupPre-surgery samplesPathological complete responseBreast cancer patientsRandomized clinical trialsPreoperative chemotherapyComplete responsePlasma protein profileResidual diseaseCancer patientsTumor responseClinical trialsBreast cancerTumor markersChemotherapySerum profileBaseline samplesCancer ResPatientsRD groupEvaluation of changesP componentProtein profilesEvaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF/MS procedure
Hawke D, Mazouni C, André F, Baggerly K, Baggerly K, Tsavachidis S, Buzdar A, Martin P, Kobayashi R, Pusztai L. Evaluation of serum profiles changes after neoadjuvant chemotherapy for breast cancer using MALDI-TOF/MS procedure. Journal Of Clinical Oncology 2009, 27: e22072-e22072. DOI: 10.1200/jco.2009.27.15_suppl.e22072.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBreast cancerPrimary chemotherapyHER2-positive patientsPathological complete responseBreast cancer cohortPositive patientsComplete responseUnnecessary toxicityResidual diseaseTumor responseCancer cohortBlood samplesChemotherapyResponse rateTreatment cyclesPosttreatment samplesCancerSerum samplesRD groupSignificant financial relationshipPatientsProfile changesRespondersTotal